United Kingdom

People: Biolife Solutions Inc (BLFS.OQ)

BLFS.OQ on NASDAQ Stock Exchange Capital Market

9:00pm BST
Change (% chg)

$-0.20 (-1.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

de Greef, Roderick 

Mr. Roderick de Greef is the Chief Financial Officer, Secretary of the Company. Mr. de Greef has over 25 years of extensive experience in corporate finance and the business world in general, as well as having served as a chief financial officer and director of a number of public and private companies. Mr. de Greef has served Elephant Talk Communications Corp., a mobile communications company, as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee since September 2015, and was previously a director of Elephant Talk from January 2008 to October 2011. Since June 2013, Mr. de Greef has served as a director and as acting Chief Financial Officer of RealAnalogics, Inc., a privately held real estate data company. From March 2015 to February 2016, Mr. de Greef was a partner of MedTech Advisors, Inc., a strategic and financial consulting firm. Since November 2013 Mr. de Greef has served as the president and sole director of Cambridge Cardiac Technologies, Inc. a privately held successor to Cambridge Heart, Inc. From November 2003 to May 2013, Mr. de Greef served as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc., a developer of minimally invasive, AAA stents. From November 2008 to October 2013, Mr. de Greef was the chairman of the board of Cambridge Heart, Inc., a manufacturer of non-invasive diagnostic cardiology products. Mr. de Greef received a Bachelor of Arts in Economics and International Relations from San Francisco State University and a Masters of Business Administration from the University of Oregon.

Basic Compensation

Total Annual Compensation, USD 345,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 175,015
Fiscal Year Total, USD 520,015

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --